Charu Aggarwal
Expertise in
18
conditions

Dr. Charu Aggarwal

Oncology
3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 
On Staff At
Accepting New Patients
Offers Telehealth
Expertise in
18
conditions
3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 

Overview

Charu Aggarwal is an Oncologist in Philadelphia, Pennsylvania. Dr. Aggarwal is highly rated in 18 conditions, according to our data. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Aggarwal is currently accepting new patients.

Her clinical research consists of co-authoring 188 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Lady Hardinge Medical College

Residency

University at Buffalo, Jacobs School of Medicine and Biomedical Sciences

Specialties

Oncology

Licenses

Internal Medicine in PA

Board Certifications

Medical Oncology, 2011

Fellowships

Fox Chase Cancer Center

Hospital Affiliations

Hospital Of Univ Of Pennsylvania
Penn Presbyterian Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
Provider Partners Health Plan
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Abramson Cancer Center Perelman 2nd Floor West
3400 Civic Center Boulevard, West Pavilion, 2nd Floor, Philadelphia, PA 19104

Additional Areas of Focus

Dr. Aggarwal has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Lung Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients
Enrollment Status: Active_not_recruiting
Publish Date: August 22, 2025
Intervention Type: Biological
Study Drug: Aglatimagene besadenovec
Study Phase: Phase 2
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Biological
Study Drugs: Enoblituzumab, Pembrolizumab, MGA012 Anti-PD-1 Antibody
Study Phase: Phase 1
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drug: 89Zr-Df-IAB22M2C
Study Phase: Phase 2
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological
Study Drugs: MGD013, MGD013+Margetuximab
Study Phase: Phase 1
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
A Study of HPV Specific Immunotherapy in Subjects With HPV6 Associated Aerodigestive Precancerous Lesions and Malignancies
A Study of HPV Specific Immunotherapy in Subjects With HPV6 Associated Aerodigestive Precancerous Lesions and Malignancies
Enrollment Status: Completed
Publish Date: November 16, 2018
Intervention Type: Biological
Study Phase: Phase 1
An Open-label, Randomized, Multicenter, Phase 1b/2b Trial Investigating the Safety and Preliminary Antitumor Effects of Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer
An Open-label, Randomized, Multicenter, Phase 1b/2b Trial Investigating the Safety and Preliminary Antitumor Effects of Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer
Enrollment Status: Withdrawn
Publish Date: August 28, 2017
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 11 Less Clinical Trials

188 Total Publications

Phase I study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers.
Phase I study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: August 12, 2025
Similar Doctors
Expertise in
14
conditions
Dr. Corey J. Langer
Oncology
Expertise in
14
conditions
Dr. Corey J. Langer
Oncology

Abramson Cancer Center Perelman 2nd Floor West

3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 
 (0.1 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Corey Langer is an Oncologist in Philadelphia, Pennsylvania. Dr. Langer is highly rated in 14 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, Small Cell Lung Cancer (SCLC), and Tissue Biopsy. Dr. Langer is currently accepting new patients.

Expertise in
27
conditions
Dr. Jakub Svoboda
Oncology
Expertise in
27
conditions
Dr. Jakub Svoboda
Oncology

University Of Pennsylvania

3400 Civic Center Blvd, 
Philadelphia, PA 
 (0.1 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jakub Svoboda is an Oncologist in Philadelphia, Pennsylvania. Dr. Svoboda is highly rated in 27 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
25
conditions
Dr. Pierluigi Porcu
Oncology
Expertise in
25
conditions
Dr. Pierluigi Porcu
Oncology

Jefferson Medical Oncology-Honickman Center

1101 Chestnut St Fl 14, 
Philadelphia, PA 
 (1.8 miles away)
215-955-8874
Languages Spoken:
English
See accepted insurances

Pierluigi Porcu is an Oncologist in Philadelphia, Pennsylvania. Dr. Porcu is highly rated in 25 conditions, according to our data. His top areas of expertise are T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Charu Aggarwal

How do I make an appointment with Dr. Charu Aggarwal?

You can book an appointment with Dr. Charu Aggarwal by calling their office at 215-615-5858. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Charu Aggarwal a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Charu Aggarwal is classified as an Elite expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Charu Aggarwal specialize in?

While Dr. Charu Aggarwal is a Oncology, they have specific expertise in Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Charu Aggarwal participate in research or clinical trials?

Yes. Dr. Charu Aggarwal has published 188 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Dr. Charu Aggarwal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Charu Aggarwal accept my insurance?

Dr. Charu Aggarwal accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 215-615-5858 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Aggarwal's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile